PATENT COOPERATION TREATY

PCT

REC'D 13 AUG 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION		on of Transmittal of International		
NEB-166-PCT			xamination Report (Form PCT/IPEA/416)		
International application No.	International filing date (day/month/year)		Priority date (day/month/year)		
PCT/US00/26900	29 September 2000 (29.09.2000)		30 September 1999 (30.09.1999)		
International Patent Classification (IPC)	or national classification and IPC				
IPC(7): C12Q 1/68, 1/48; C12P 19/34;	C12N 15/01 and US Cl.: 435/6, 15	<u>, 91.1, 183, 19</u>	3, 194		
Applicant					
NEW ENGLAND BIOLABS, INC.					
1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.					
2. This REPORT consists of	a total ofsheets, including	this cover she	et.		
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of Sheets.					
3. This report contains indicate	ations relating to the following i	tems:			
J. This report contains muse	ations forming to the form was -				
I 🔀 Basis of the rep	юrt				
II Priority					
III Non-establishm	III Non-establishment of report with regard to novelty, inventive step and industrial applicability				
IV Lack of unity o	IV Lack of unity of invention				
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
VI Certain documents cited					
VII Certain defects in the international application					
VIII Certain observations on the international application					
	••				
Data of submission of the demand	Date	of completion	of this report		
Date of submission of the demand	Date	or completion	or uns report		
12 April 2001 (12.04.2001)	1034	ly 2001 (10.07.			
Name and mailing address of the IPEA/US Authorized ffice Authorized fice Auth					
Commissioner of Patents and Trademarks Box PCT Westigator D. G. 20031			murthy $oldsymbol{\mathcal{U}}$		
Washington, D.C. 20231 Facsimile No. (703)305-3230	Facsimile No. (703)305-3230 Telephone No. (703) 308-0196				
Form PCT/IPEA/409 (cover sheet)(July	1998) €				



International application No.	
PCT/US00/26900	

I.	Basi	s of the report		
1.	With	regard to the elements of the international application:*		
	\boxtimes	the international application as originally filed.		
	\boxtimes	the description:		
		pages 1-46 as originally filed		
		pages NONE, filed with the demand pages NONE, filed with the letter of		
	\triangle	the claims:		
		pages 47-50 , as originally filed pages NONE , as amended (together with any statement) under Article 19		
		pages NONE , filed with the demand		
		pages NONE , filed with the letter of		
	\boxtimes	the drawings:		
	_	pages 1-13, as originally filed		
		pages NONE , filed with the demand		
		pages NONE , filed with the letter of		
	\bowtie	the sequence listing part of the description:		
		pages 1-9 , as originally filed pages NONE , filed with the demand		
		pages NONE , filed with the letter of		
2.	Wit	h regard to the language, all the elements marked above were available or furnished to this Authority in the		
	lang	uage in which the international application was filed, unless otherwise indicated under this item.		
	The	se elements were available or furnished to this Authority in the following language which is:		
		the language of a translation furnished for the purposes of international search (under Rule23.1(b)).		
		the language of publication of the international application (under Rule 48.3(b)).		
		the language of the translation furnished for the purposes of international preliminary examination(under Rules		
		55.2 and/or 55.3).		
3.	Wit	th regard to any nucleotide and/or amino acid sequence disclosed in the international application, the mational preliminary examination was carried out on the basis of the sequence listing:		
	\boxtimes	contained in the international application in printed form.		
	$\overline{\boxtimes}$	filed together with the international application in computer readable form.		
		furnished subsequently to this Authority in written form.		
	\sqcap	furnished subsequently to this Authority in computer readable form.		
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the		
		international application as filed has been furnished.		
		The statement that the information recorded in computer readable form is identical to the written sequence listing		
		has been furnished.		
4.		The amendments have resulted in the cancellation of:		
		the description, pages NONE		
		the claims, Nos. NONE		
		the drawings, sheets/fig NONE		
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go		
*	Panl.	beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).** accement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in		
thi	this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). ** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.			



nternational	application	No.

PCT/US00/26900

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:			
	the entire international application,		
\boxtimes	claims Nos. <u>8-18 and 27-31</u>		
becau	se:		
	the said international application, or the said claim Nos relate to the following subject matter which does not require international preliminary examination (specify):		
	the description, claims or drawings (indicate particular elements below) or said claims Nos are so unclear that no meaningful opinion could be formed (specify):		
	$a_{\mu} = a_{\mu}$		
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.		
\boxtimes	no international search report has been established for said claims Nos. 8-18 and 27-31		
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:			
	the written form has not been furnished or does not comply with the standard.		
	the computer readable form has not been furnished or does not comply with the standard.		

Form PCT/IPEA/409 (Box III) (July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/26900

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1. STATEMENT					
Novelty (N)	Claims Claims	1-7 and 19-26 NONE	YES NO		
Inventive Step (IS)	Claims Claims	1-7 and 19-26 NONE	YES NO		
Industrial Applicability (IA)		1-7 and 19-26 NONE	YES NO		
2. CITATIONS AND EXPLANATIONS (Rul Claims 1-7 and 19-26 meet the criteria set out in PC method for site specific incorporation of derivatized polymerase, a primed DNA template and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide derivatized dideoxynucleotide is incorporated more of the complete and nucleotide derivatized dideoxynucleotide derivatized derivatized derivatized derivatized derivatized derivatized derivatized d	T Article 33(2 dideoxynucleous solution conta efficiently than	otides into DNA comprising reacting an a ining at least one derivatized dideoxynuc	rchaeon Family B DNA leotide wherein the		
NONE					
	-		·		
	₹. €	<u></u>			

Form PCT/IPEA/409 (Box V) (July 1998)